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prepubertal, m easuring 2 cm long and 1.2 cm wide (vol-
ume 1.5 ml).
We made a clinical diagnosis of simple virilising congeni-
tal adrenal hyperplasia and gave a small dose of hydrocorti-
sone, pending the results of blood and urine tests. Bone age, 
assessed by the TW2 system of Tanner and Whitehouse,2 
showed a relatively modest advance at 7.3 years (chrono-
logical age 4.8 years). Serum 17-hydroxyprogesterone and 
cortisol concentrations before and after stimulation with 
synthetic adrenocorticotrophic hormone were 6/13 and 
131/717 nmol/l respectively, excluding classic 21-hydroxy-
lase deficient congenital adrenal hyperplasia. Serum andro-
gens showed androstenedione <1.4 nmol/l (normal range 
<2 nmol/l), dehydroepiandrosterone sulphate (DHAS) <0.8 
µmol/l (<2 µmol/l), testosterone 6.4 nmol/l (<0.7 nmol/l). 
The luteinising hormone and follicle stimulating hormone 
response to luteinising hormone releasing hormone (LHRH) 
stimulation was prepubertal, with all values below 1.4 U/l. 
Urine steroid profile was unremarkable.
These findings did not support the initial diagnosis of 
simple virilising congenital adrenal hyperplasia, and hydro-
cortisone treatment was stopped. At follow-up the child’s 
mother volunteered the information that the father had been 
receiving testosterone gel 50 mg daily and that the child had 
been sleeping in the parents’ bed for the past six months 
while major structural repair to the house, involving the 
child’s bedroom, was being carried out. C ontact with the 
lesson oF the Week
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Caution men treated with testosterone  
gel to wear clothing when in close contact 
with children
A boy aged 4.8 years was referred by his general 
 practitioner with a year’s history of progressive pubic hair 
development and increase in length and width of the penis 
(figure).  Parents had also noticed a growth spurt in the pre-
vious year; the boy was now wearing age 6-7 clothes and 
his shoe size had increased during the past six months. 
There was no axillary hair, acne, or body odour.
The mother was aged 43 years and in good health. The 
father, aged 50, had undergone pituitary surgery and 
radiotherapy followed by bilateral adrenalectomy for 
 Cushing’s disease at the age of 19 and was receiving hor-
mone replacement therapy for adrenal insufficiency and 
central hypogonadism.
On examination the boy measured 115.1 cm and 
weighed 23.8 kg. Both these measurements are above the 
97th centile, according to current UK growth sta ndards, 
with height well above the range expected for the parents’ 
heights (mother 3rd-10th centile, father 10th centile). 
The penis was 5.5 cm long and 6.5 cm in circ umference, 
 equivalent to T anner stage G41 (see box); pubic hair Tan-
ner stage 3-4; ax illary hair Tanner stage 1. Testes were 
Genitalia of 4 year old boy exposed to testosterone gel 
showing penile enlargement (Tanner stage G4) and pubic hair 
development (Tanner stage P4)
Tanner stages of puberty in boys1
Genital staging
G1 Prepubertal penis, scrotum, and testes (volume ≤3 ml)
G2 Testes ≥4 ml with scrotal laxity, but no penile 
enlargement
G3 Penile lengthening with further development of testes 
and scrotum
G4 Penile lengthening and broadening, further 
development of the testes (volume usually 10-12 ml)
G5 Adult genitalia, testes 15-25 ml
Pubic hair staging
P1 No pubic hair
P2 Fine hair over mons or scrotum
P3 Adult type hair (coarse, curly) but distribution confined 
to pubis
P4 Extension to near adult distribution
P5 Adult
Axillary hair staging
A1 No axillary hair
A2 Hair present but not adult amount
A3 Adult
bmj.com archive
recent lesson of the week 
articles
• Copper deficiency as 
a treatable cause of poor 
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• Treatment for lymph 
node tuberculosis (BMJ 
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• Tachycardia due to atrial 
flutter with rapid 1:1 conduction 
following treatment of atrial 
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testosterone gel was discontinued. When the boy was reas-
sessed at 5.1 years, the penis was 7 cm long and 7.5 cm in 
circumference, testes were unchanged in volume, and height 
velocity was 10 cm/year. Basal testosterone had fallen to 0.7 
nmol/l; other serum androgens were low or unrecordable. 
At 5.5 years the boy’s pubic hair had regressed to Tanner 
stage 2, penile length was 6 cm and circumference was 7 
cm, and height velocity was 5.3 cm/year. Testes were 2 ml 
in volume.
Discussion
Testosterone gels are approved for use in men with congeni-
tal or acquired primary and secondary hypogonadism who 
need substitution therapy and have the advantage of avoid-
ing the need for painful intramuscular injections. Passive 
hormone transfer from skin to skin contact is a recognised 
adverse event in children3-5 and female partners,6 but the risk 
is greatly reduced by washing the skin within 10 minutes after 
application7 and by wearing clothing (sleeping in pyjamas, for 
example). Current label instructions advise patients to apply 
testosterone gel topically to the shoulders, upper arms, or 
abdomen and then to wash their hands and cover the treated 
area with clothing. 
Despite the new label precautions imposed by the US 
Food and Drug Administration (FDA) in May 2008, eight 
new reports of children being exposed to testosterone were 
received in the following six months.8 Most cases were attrib-
utable to patients failing to follow the label instructions, and 
being unaware of the risk.4 Although symptoms regressed 
when testosterone exposure was stopped in most of the eight 
cases reported to the FDA, residual genital enlargement and 
advanced bone age were recorded in a few.3 In their publica-
tion of five cases, Kunz et al reported two children as having an 
advanced bone age at the time of initial presentation.4 Among 
the three children in whom clinical examination after discon-
tinuation of exposure to androgens was documented, one girl 
showed regression of virilisation, and one boy and the other 
girl showed no change two and four months after contact with 
androgen had been discontinued. More over, many children 
had undergone invasive procedures to determine the cause of 
their symptoms before the correct diagnosis was made.
Our case highlights the serious clinical consequences of 
contamination by transdermal testosterone in a child. The 
clinical presentation resembled simple virilising congenital 
adrenal hyperplasia. However, the normal serum 17-hydroxy-
progesterone and absence of extreme bone age advance were 
not consistent with the diagnosis, and the absence of raised 
serum adrenal steroids or urinary steroid metabolites also 
pointed to a non-adrenal cause. In the context of normal pre-
pubertal testes, the raised concentration of testosterone was 
initially hard to explain, although testotoxicosis or a very small 
Leydig cell tumour were possible diagnoses. Until the mother 
volunteered the information about the father’s medication 
we were considering more invasive investigation, including 
selective venous sampling from the testicular veins.
In the light of increased use of transdermal testosterone 
products to influence libido, muscle strength, and behav-
iour,9 we advise extra vigilance in counselling patients as to 
unwanted side effects. This case underlines the importance 
of taking a careful drug history from the family members of 
children presenting with sexual precocity.
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I was listening to a guest lecture by an acclaimed 
professor on groundbreaking research—work that is 
probably going to save a whole generation of currently 
unsalvageable patients. The research seemed well 
founded and is going to be implemented soon. It 
has got huge funding and seems to have ticked all 
the necessary boxes. The only slight hitch is that it 
is still undergoing a randomised control trial in a 
remote village in India. Everyone in the audience sat 
mesmerised, while my thoughts went miles away.
As a graduate from a state run medical college in 
India, I have seen the hardships that the peasants 
endure. With sparse medical knowledge and sparser 
money but abundant respect for life for their loved 
ones, they treat doctors as gods and hang on to any 
ray of hope offered. They are unassuming and do not 
doubt or question the treatment being offered. In such 
situations “ethical approval” may not be stringent and 
in some cases may not be needed at all.
As I sat viewing the slides of this village in India 
and the recruits (nurses and patients), I was 
struck by their naivety and innocence. They will 
have unquestioning faith in a professor from a top 
university in England.
If the research is good enough to be implemented 
in our hospitals, I am sure it is more sensible to 
do a clinical trial here, under pretty much similar 
conditions and cohort of patients. This is a common 
short cut employed by many. Do you think it’s right?
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